Do analysts rate APLT or KVAC?

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, equities research analysts plainly believe Applied Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, APLT or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than Applied Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Applied Therapeutics $1M 15.86 -$105.62M -$0.10 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is APLT or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Keen Vision Acquisition N/A N/A N/A

Is BOLD or APLT more profitable?

Boundless Bio's return on equity of -65.05% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -65.05% -41.14% Applied Therapeutics N/A -340.84% -175.00%

Is PMVP or APLT more profitable?

PMV Pharmaceuticals' return on equity of -68.98% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -68.98% -62.70% Applied Therapeutics N/A -340.84% -175.00%

Is APLT or IMA more profitable?

ImageneBio's return on equity of -38.99% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% ImageneBio N/A -38.99% -34.84%

Is APLT or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Rein Therapeutics N/A N/A -68.14%

Applied Therapeutics (APLT) Competitors

$0.10 0.00 (0.00%)

As of 08/7/2026

Compare

APLT vs. KVAC, BOLD, PMVP, IMA, and RNTX

Should you buy Applied Therapeutics stock or one of its competitors? MarketBeat compares Applied Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Applied Therapeutics include Keen Vision Acquisition (KVAC), Boundless Bio (BOLD), PMV Pharmaceuticals (PMVP), ImageneBio (IMA), and Rein Therapeutics (RNTX). These companies are all part of the "biotechnology" industry.

How does Applied Therapeutics compare to Keen Vision Acquisition?

Applied Therapeutics (NASDAQ:APLT) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Keen Vision Acquisition has lower revenue, but higher earnings than Applied Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Applied Therapeutics' average media sentiment score of 0.00 equaled Keen Vision Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Keen Vision Acquisition	Neutral

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

Keen Vision Acquisition's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Keen Vision Acquisition	N/A	N/A	N/A

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, equities research analysts plainly believe Applied Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Applied Therapeutics and Keen Vision Acquisition tied by winning 4 of the 8 factors compared between the two stocks.

How does Applied Therapeutics compare to Boundless Bio?

Boundless Bio (NASDAQ:BOLD) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Boundless Bio's return on equity of -65.05% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-65.05%	-41.14%
Applied Therapeutics	N/A	-340.84%	-175.00%

Boundless Bio has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Boundless Bio currently has a consensus target price of $4.00, indicating a potential upside of 40.35%. Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

98.3% of Applied Therapeutics shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Boundless Bio had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Boundless Bio and 0 mentions for Applied Therapeutics. Boundless Bio's average media sentiment score of 1.08 beat Applied Therapeutics' score of 0.00 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Positive
Applied Therapeutics	Neutral

Boundless Bio has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Summary

Boundless Bio beats Applied Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Applied Therapeutics compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, PMV Pharmaceuticals' average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
PMV Pharmaceuticals	Neutral
Applied Therapeutics	Neutral

PMV Pharmaceuticals has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

PMV Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 231.95%. Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

PMV Pharmaceuticals' return on equity of -68.98% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Applied Therapeutics	N/A	-340.84%	-175.00%

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PMV Pharmaceuticals has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Summary

PMV Pharmaceuticals beats Applied Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Applied Therapeutics compare to ImageneBio?

Applied Therapeutics (NASDAQ:APLT) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Applied Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 870.87%. ImageneBio has a consensus target price of $30.00, indicating a potential upside of 435.24%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

ImageneBio has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
ImageneBio	$800K	74.62	-$45.35M	-$5.79	N/A

In the previous week, ImageneBio had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for ImageneBio and 0 mentions for Applied Therapeutics. ImageneBio's average media sentiment score of 1.00 beat Applied Therapeutics' score of 0.00 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
ImageneBio	Positive

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ImageneBio's return on equity of -38.99% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
ImageneBio	N/A	-38.99%	-34.84%

Summary

ImageneBio beats Applied Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to Rein Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Rein Therapeutics has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Rein Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Rein Therapeutics	N/A	N/A	-68.14%

Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Applied Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Rein Therapeutics has a consensus price target of $6.00, indicating a potential upside of 668.25%. Given Applied Therapeutics' higher possible upside, equities analysts plainly believe Applied Therapeutics is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Rein Therapeutics had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Rein Therapeutics and 0 mentions for Applied Therapeutics. Rein Therapeutics' average media sentiment score of 0.15 beat Applied Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Rein Therapeutics	Neutral

Summary

Rein Therapeutics beats Applied Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLT vs. The Competition

Export

Metric	Applied Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.86M	$3.71B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.03	9.08	269.95	24.78
Price / Sales	15.86	1,267.38	650.49	107.95
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.21	17.64	11.25	6.43
Net Income	-$105.62M	-$13.25M	$3.45B	$347.27M
7 Day Performance	N/A	5.21%	3.49%	2.53%
1 Month Performance	N/A	-1.94%	-0.66%	-1.03%
1 Year Performance	-75.80%	60.76%	77.20%	23.28%

Applied Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLT Applied Therapeutics	1.5243 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
BOLD Boundless Bio	3.2166 of 5 stars	$2.84 +1.4%	$4.00 +40.8%	+163.9%	$62.90M	N/A	N/A	64	Positive News Earnings Report Analyst Downgrade
PMVP PMV Pharmaceuticals	3.3642 of 5 stars	$1.18 +0.9%	$4.00 +239.0%	-19.6%	$62.40M	N/A	N/A	50
IMA ImageneBio	2.6047 of 5 stars	$5.63 -2.1%	$30.00 +432.9%	-61.2%	$61.26M	$800K	N/A	70	Positive News Earnings Report Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Applied Therapeutics (APLT) Competitors

APLT vs. KVAC, BOLD, PMVP, IMA, and RNTX

How does Applied Therapeutics compare to Keen Vision Acquisition?

Summary

How does Applied Therapeutics compare to Boundless Bio?

Summary

How does Applied Therapeutics compare to PMV Pharmaceuticals?

Summary

How does Applied Therapeutics compare to ImageneBio?

Summary

How does Applied Therapeutics compare to Rein Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Applied Therapeutics (APLT) Competitors

APLT vs. KVAC, BOLD, PMVP, IMA, and RNTX

How does Applied Therapeutics compare to Keen Vision Acquisition?

Which has higher earnings and valuation, APLT or KVAC?

Does the media prefer APLT or KVAC?

Do insiders & institutionals have more ownership in APLT or KVAC?

Which has more risk & volatility, APLT or KVAC?

Is APLT or KVAC more profitable?

Do analysts rate APLT or KVAC?

Summary

How does Applied Therapeutics compare to Boundless Bio?

Is BOLD or APLT more profitable?

Which has higher valuation and earnings, BOLD or APLT?

Do analysts rate BOLD or APLT?

Do institutionals and insiders believe in BOLD or APLT?

Does the media refer more to BOLD or APLT?

Which has more risk and volatility, BOLD or APLT?

Summary

How does Applied Therapeutics compare to PMV Pharmaceuticals?

Does the media refer more to PMVP or APLT?

Which has higher earnings & valuation, PMVP or APLT?

Do analysts recommend PMVP or APLT?

Is PMVP or APLT more profitable?

Do insiders and institutionals hold more shares of PMVP or APLT?

Which has more volatility & risk, PMVP or APLT?

Summary

How does Applied Therapeutics compare to ImageneBio?

Which has more risk & volatility, APLT or IMA?

Do analysts recommend APLT or IMA?

Which has stronger earnings and valuation, APLT or IMA?

Does the media refer more to APLT or IMA?

Do institutionals and insiders believe in APLT or IMA?

Is APLT or IMA more profitable?

Summary

How does Applied Therapeutics compare to Rein Therapeutics?

Which has better valuation and earnings, APLT or RNTX?

Is APLT or RNTX more profitable?

Which has more volatility & risk, APLT or RNTX?

Do insiders and institutionals believe in APLT or RNTX?

Do analysts recommend APLT or RNTX?

Does the media refer more to APLT or RNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools